Exon 20-Mutated NSCLC: Extending the Data Set to Allow the Recognition of Potential Causes

Exon 20-Mutated NSCLC: Extending the Data Set to Allow the Recognition of Potential Causes

Bibliographic Details
Main Authors:	Nico van Zandwijk, PhD, MD, FRACP, FCCP, Christopher I. Amos, PhD, Oluf Dimitri Røe, MD, PhD, Glen Reid, PhD, Sonja Klebe, MD, PhD, FRCPA, FFSc
Format:	Article
Language:	English
Published:	Elsevier 2023-04-01
Series:	JTO Clinical and Research Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364323000395

Similar Items

Extending the EXOTIC Database to Allow the Recognition of Potential Causes of Exon 20-Mutated NSCLC
by: Giannis Mountzios, MD, PhD
Published: (2023-05-01)

Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing
by: So Yeon Kim, MD, et al.
Published: (2022-09-01)

Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry
by: Giannis Mountzios, MD, PhD, et al.
Published: (2023-01-01)

RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants
by: Kazumi Nishino, MD, PhD, et al.
Published: (2024-02-01)

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
by: Sai-Hong Ignatius Ou, MD, et al.
Published: (2023-10-01)

RET Fusion Testing in Patients With NSCLC: The RETING Study
by: Esther Conde, MD, PhD, et al.
Published: (2024-04-01)

Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060
by: Takehiro Tozuka, MD, et al.
Published: (2024-04-01)

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
by: Véronique Hofman, MD, PhD, et al.
Published: (2023-02-01)

Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases
by: Marcin Nicoś, PhD, et al.
Published: (2022-12-01)

Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC
by: Hitomi Jo, MD, PhD, et al.
Published: (2023-04-01)

Detection of Tumor DNA in Bronchoscopic Fluids in Peripheral NSCLC: A Proof-of-Concept Study
by: Gwenaëlle Arhant, MD, et al.
Published: (2024-02-01)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
by: Yuhei Kinehara, MD, PhD, et al.
Published: (2023-11-01)

Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report
by: Masahiro Torasawa, MD, et al.
Published: (2024-04-01)

Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study
by: Yuki Katayama, MD, PhD, et al.
Published: (2024-03-01)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
by: Tomoki Kuge, MD, et al.
Published: (2023-05-01)

Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy
by: Junko Tanizaki, MD, PhD, et al.
Published: (2023-12-01)

Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)
by: Satoru Miura, MD, PhD, et al.
Published: (2023-03-01)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
by: Kenji Morimoto, MD, PhD, et al.
Published: (2022-09-01)

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
by: Hidetoshi Hayashi, MD, PhD, et al.
Published: (2023-04-01)

Racial and Ethnic Trends and Disparities in NSCLC
by: Kristin M. Primm, MPH, PhD, et al.
Published: (2022-08-01)

Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
by: M. Jebbink, MD, et al.
Published: (2023-04-01)

Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)
by: Jiyun Lee, MD, et al.
Published: (2022-01-01)

Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L)
by: Motoko Tachihara, MD, PhD, et al.
Published: (2023-10-01)

Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects
by: Lysanne A. Lievense, MD, PhD, et al.
Published: (2023-01-01)

Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC
by: Yuto Terashima, MD, et al.
Published: (2023-11-01)

The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
by: Yosuke Kagawa, MD, et al.
Published: (2023-03-01)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
by: Toshiaki Takakura, MD, et al.
Published: (2023-06-01)

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial
by: Makoto Hibino, MD, et al.
Published: (2022-12-01)

Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC
by: Judith L. Gulikers, MSc, et al.
Published: (2024-04-01)

Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets
by: Bingnan Zhang, MD, MBA, et al.
Published: (2024-02-01)

A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L)
by: Kazushige Wakuda, MD, et al.
Published: (2023-12-01)

Prognostic Significance of the Proposed Residual Tumor Classification in Patients With NSCLC After Sleeve Lobectomy
by: Tao Chen, PhD, et al.
Published: (2023-10-01)

Improving Lung Cancer Screening Selection: The HUNT Lung Cancer Risk Model for Ever-Smokers Versus the NELSON and 2021 United States Preventive Services Task Force Criteria in the Cohort of Norway: A Population-Based Prospective Study
by: Olav Toai Duc Nguyen, MD, et al.
Published: (2024-04-01)

Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC
by: Edward S. Kim, MD, et al.
Published: (2022-01-01)

Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC
by: Lee S. Schwartzberg, MD, et al.
Published: (2022-09-01)

Evaluate the Prognosis of Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study
by: Jin Cao MS, et al.
Published: (2022-12-01)

Comment on The Unbearable Lightness of Difference Between Statistical and Clinical Significance
by: Luca Bertolaccini, MD, PhD, FCCP, et al.
Published: (2022-03-01)

Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression
by: Timothy Rajakumar, MD, PhD, et al.
Published: (2022-08-01)

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
by: Marina C. Garassino, MD, et al.
Published: (2023-01-01)

Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study
by: Shunsuke Teraoka, MD, et al.
Published: (2024-03-01)